CN1146410C - 控制释放制剂 - Google Patents
控制释放制剂 Download PDFInfo
- Publication number
- CN1146410C CN1146410C CNB991066421A CN99106642A CN1146410C CN 1146410 C CN1146410 C CN 1146410C CN B991066421 A CNB991066421 A CN B991066421A CN 99106642 A CN99106642 A CN 99106642A CN 1146410 C CN1146410 C CN 1146410C
- Authority
- CN
- China
- Prior art keywords
- tramadol
- active component
- preparation
- granule
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于口服给药的控制释放制剂,它含有反胺苯环醇或其可药用盐作为活性成分。
Description
技术领域
本发明涉及用于口服给药的控制释放制剂、其制备方法及其医疗应用。具体地讲,本发明涉及包含反胺苯环醇(tramdol)或其可药用盐的控制释放制剂。
背景技术
反胺苯环醇,其化学名为(±)-反式-2-[(二甲基氨基)甲基]-1-(3-甲氧基苯基)环己醇,是一种口服活性鸦片类(opioid)止痛药。含有反胺苯环醇或者更具体地讲含有其盐酸盐的常规释放的胶囊剂、滴剂和栓剂已经市售了许多年,用于治疗中度疼痛至剧痛;但是这类制剂不能控制释放反胺苯环醇。此外,尽管长期使用反胺苯环醇,但是含有反胺苯环醇作为活性成分的用于口服给药的控制释放制剂以前甚至从未在文献中描述过。
发明内容
本发明的一个目的是提供了适于至少每12小时(例如最高达24小时)给药一次的用于治疗疼痛的口服控制释放反胺苯环醇制剂。
因此本发明提供了包含反胺苯环醇或其可药用盐的用于口服给药的控制释放制剂。
适用于本发明的反胺苯环醇的可药用盐是本领域中通常已知的那些可药用盐,例如可药用酸加成盐。特别优选盐酸盐。
本发明的控制释放制剂是延长的时间期间内可达到药物的缓慢释放的制剂,因此对比常规释放的药物而言延长了药物作用的持续时间。优选的此类制剂在12小时或更长的治疗时间内保持血药浓度。
本发明人发现,为了在口服给药后至少12小时期间能够控制释放反胺苯环醇,体外释放速率优选相应于下列反胺苯环醇的释放速率%:
表1 | |
时间(小时) | 释放% |
1 | 0-50 |
2 | 0-75 |
4 | 3-95 |
8 | 10-100 |
12 | 20-100 |
16 | 30-100 |
24 | 50-100 |
36 | >80 |
尤其适用于每天两次给药的另一类优选的制剂具有相应于下列反胺苯环醇释放速率%的体外释放速率:
表2 | |
时间(小时) | 释放% |
1 | 20-50 |
2 | 40-75 |
4 | 60-95 |
8 | 80-100 |
12 | 90-100 |
特别适用于每天一次给药的另一类优选的制剂具有相应于下列反胺苯环醇释放速率%的体外释放速率:
表3 | |
时间(小时) | 释放% |
1 | 0-50 |
2 | 0-75 |
4 | 10-95 |
8 | 35-100 |
12 | 55-100 |
16 | 70-100 |
24 | >90 |
此外,本发明还有一类优选的、也特别适用于每天一次给药的制剂具有相应于下列反胺笨环醇释放速率%的体外释放速率:
表4 | |
时间(小时) | 释放% |
1 | 0-30 |
2 | 0-40 |
4 | 3-55 |
8 | 10-65 |
12 | 20-75 |
16 | 30-88 |
24 | 50-100 |
36 | >80 |
每天一次给药的更优选的制剂具有基本如下的体外释放速率:
表5 | |
时间(小时) | 反胺苯环醇释放% |
1 | 10-30 |
2 | 17-37 |
4 | 27-47 |
8 | 40-60 |
12 | 49-69 |
15 | 57-77 |
本发明每天两次给药的控制释放制剂一旦释放,另一种优选的体外溶解速率是:1小时后反胺苯环醇释放5-50%(重量)、2小时后反胺苯环醇释放10-75%(重量)、4小时后反胺苯环醇释放20-95%(重量)、8小时后反胺苯环醇释放40-100%(重量)、12小时后反胺苯环醇释放超过50%(重量)、18小时后反胺苯环醇释放超过70%(重量)、24小时后反胺苯环醇释放超过80%(重量)。
另外,在每天两次给药的控制释放制剂的情况下,优选的是:口服给药8小时后在体内吸收70-95%(重量)反胺苯环醇、10小时后吸收77-97%(重量)反胺苯环醇、12小时后吸收80-100%(重量)反胺苯环醇。
适于每天两次给药的本发明制剂的tmax可为1.5-8小时,优选2-7小时,W50值为7-16小时。
适于每天一次给药的本发明制剂的tmax可为3-16小时,优选4-5小时,W50值为10-33小时。
参数W50定义了在50%Cmax的血浆分布图的宽度,即血浆浓度等于或大于50%峰浓度的持续时间。该参数是通过所测数据的线性内推法测定的,它表示在血浆分布图中在第一个(或唯一的)上斜面交叉与最后一个(或唯一的)下斜面交叉之间的时间差。
除非另外指明,本文所提及的体外释放速率是采用Ph.Eur。Paddle方法在100rpm在900ml 0.1N盐酸中在37℃以及在270nm处采用UV检测得到的。
本发明的控制释放制剂优选含有止痛有效量的反胺苯环醇或其可药用盐,通常每个剂量单位含有50-800mg,特别是100、200、300、400至600mg(以反胺苯环醇盐酸盐计)。
本发明的控制释放制剂可以是例如粒剂、球剂(spheroids)、小丸剂、多颗粒剂、胶囊剂、片剂、香囊剂(sachets)、控制释放悬浮液剂,或为结合这类粒剂、球剂、小丸剂或多颗粒剂的任何其他适宜的剂型。
本发明制剂中的活性成分适于与基质结合。基质可以是任何能在至少12小时期间内控制释放反胺苯环醇的基质,优选能提供在上述范围内的反胺苯环醇的体外溶解速率和体内吸收速率的基质。优选该基质为控制释放基质。或者可以使用带有包衣的正常释放基质,该包衣可以控制释放活性成分。
包括在控制释放基质中的适宜物质包括:
(a)亲水性或疏水性聚合物,如树胶、纤维素醚、丙烯酸树脂和蛋白质衍生物质。在这些聚合物中,优选纤维素醚,特别是烷基纤维素。该制剂通常可含有1%-80%(重量)的一种或多种亲水性或疏水性聚合物。
(b)可消化的、长链(C8-C50、特别是C12-C40)、取代或未取代的烃类如脂肪酸、脂肪醇、脂肪酸甘油酯、矿物和植物油及蜡。熔点为25-90℃的烃类是优选的。在这些长链烃物质中,脂肪(脂族)醇是优选的。该制剂通常可含有最多达60%(重量)的至少一种可消化的长链烃。
(c)聚二醇。该制剂适于含有最多达60%(重量)的一种或多种聚二醇。
一种特别适宜的控制释放基质包含一种或多种烷基纤维素和一种或多种C12-C36脂族醇。烷基纤维素优选C1-C6烷基纤维素,特别是乙基纤维素。本发明的控制释放制剂优选含有1-20%(重量)、特别是2-15%(重量)的一种或多种烷基纤维素。
脂族醇一般可以是月桂醇、肉豆蔻醇或硬脂醇,但是优选为鲸蜡醇,或更优选鲸蜡醇硬脂醇混合物(cetostearyl alcohol)。该控制释放制剂适于含有5-30%(重量)脂族醇,优选10-25%(重量)脂族醇。
该控制释放基质还可任选含有药物领域中常用的其他可药用成分,例如稀释剂、润滑剂、粘合剂、制粒助剂、着色剂、调味剂、表面活性剂、pH调节剂、抗粘连剂和滑动剂(glidants),如癸二酸二丁酯、氢氧化铵、油酸和胶体二氧化硅。
本发明的控制释放制剂通常可以用药物领域中常用的任何膜包衣材料进行膜包衣。优选使用含水膜包衣。
或者,本发明的控制释放制剂可以包含具有控制释放包衣的正常释放基质。优选该制剂包含含有活性成分和成球剂的膜包衣球剂。
成球剂可以是可与活性成分团成球以形成球剂的任何适宜的可药用物质。优选的成球剂是微晶纤维素。所用微晶纤维素可以是例如Avicel PH 101或Avicel PH 102(商标,FMC Corporation)。
所述球剂可任选含有药物领域常用的其他可药用成分,例如粘合剂、填充剂和着色剂。适宜的粘合剂包括水溶性聚合物、水溶性羟烷基纤维素如羟丙基纤维素或水不溶性聚合物(它也可以具有控制释放性质)如丙烯酸聚合物或共聚物例如乙基纤维素。适宜的填充剂包括乳糖。
所述球剂用一种可使活性成分在含水介质中以控制的速度释放的材料包衣。适宜的控制释放包衣材料包括水不溶性蜡和聚合物如聚甲基丙烯酸酯(例如Eudragit polymers,商标),或水不溶性纤维素,特别是乙基纤维素。可任选包括水溶性聚合物如聚乙烯吡咯烷酮或水溶性纤维素如羟丙基甲基纤维素或羟丙基纤维素。可以任选加入其他水溶性试剂如多乙氧基醚。
或者可以将药物包覆成惰性non-pareil小丸,并且用可使活性成分向含水介质中控制释放的物质包覆该装有药物的小丸。
另一方面,本发明提供了制备本发明控制释放制剂的方法,该方法包含在控制释放基质中掺入反胺苯环醇或其可药用盐,例如:
(a)将包含反胺苯环醇或其可药用盐以及一种或多种烷基纤维素的混合物制粒;
(b)将含有烷基纤维素的颗粒与一种或多种C12-36脂族醇混合;以及任选
(c)使颗粒成型并压制颗粒,并且如果需要,进行膜包衣;或者
(d)将包含反胺笨环醇或其可药用盐、乳糖和一种或多种烷基纤维素以及一种或多种C12-36脂族醇的混合物制粒;以及任选
(e)将所述颗粒成型并压制颗粒,并且如果需要进行膜包衣。
本发明控制释放制剂也可以通过下述方法制备成膜包衣球剂:
(a)将包含反胺苯环醇或其可药用盐以及成球剂的混合物制粒;
(b)挤压制粒混合物,得到挤出物;
(c)将挤出物团成球直至形成球状体;以及
(d)用膜包衣包覆这些球状体。
本发明优选的单位剂型的形式包含装有控制释放颗粒的胶囊剂,该颗粒主要包含活性成分、疏水性易熔的载体或稀释剂,以及任选含有亲水性释放调节剂。特别是,该控制释放颗粒优选通过下述方法制备,该方法包含:使干燥的活性成分与易熔的释放控制材料形成混合物,然后在高速混合器中对混合物进行机械加工,同时输入足以使易熔材料溶融或软化的能量,以使其与活性成分形成颗粒。将所得颗粒冷却后进行适当过筛,得到大小为0.1-3.0mm、优选0.25-2.0mm的颗粒。下面描述了本发明的一个实例,它适用于剂量单位的工业化生产。
本发明的一个优选实施方案是一种单剂形式的药物制剂,包括含颗粒尺寸为0.1至3.0毫米的多枚颗粒的片剂或胶囊剂,且含有作为活性成分的反胺苯环醇或其药物可接受盐,该活性成分包含在药物可接受赋形剂基质中,其特征在于该活性成分是反胺苯环醇或其药物可接受盐,该单剂含有50-400毫克反胺苯环醇,反胺苯环醇按照反胺苯环醇盐酸盐计算,且该基质主要由疏水可熔融物质组成,选自氢化植物油、氢化蓖麻油、微晶蜡、蜂蜡、巴西棕榈蜡和甘油单硬脂酸酯,活性物质总量占制剂重量的10%-90%。
当使用该加工技术时发现,为了最容易地达到所需的释放特性(如上所讨论的体内与体外释放特性),所加工的组合物应该包含两种基本成分,即:
(a)反胺苯环醇或其盐;和
(b)疏水性易熔载体或稀释剂;以及任选
(c)释放控制成分,它包含水溶性易熔材料或可溶解颗粒或不溶解颗粒的有机或无机材料。
我们已发现,反胺苯环醇或其可药用盐在组合物中的总量可以在很宽范围内变化,例如占组合物的10-90%(重量)。
疏水性易熔成分(b)应该是疏水材料,如天然的或合成的蜡或油,例如氢化植物油、氢化蓖麻油、微晶蜡、蜂蜡、巴西棕榈蜡和一硬脂酸甘油酯,并且适合的熔点为35-140℃、优选45-110℃。
当释放调节成分(c)是水溶性易熔材料时,一般为聚乙二醇;而当其是颗粒材料时,一般为可药用材料如磷酸二钙或乳糖。
制备本发明制剂的另一优选方法包含:
(a)将颗粒形式的反胺苯环醇或其可药用盐与熔点为35-140℃的颗粒状疏水性易熔载体或稀释剂以及任选与释放控制成分(包含水溶性易熔材料或可溶解颗粒的或不溶解颗粒的有机或无机材料)的混合物,以能使载体或稀释剂熔融或软化的速度和能量输入在高速混合物中进行机械加工,使其形成附聚物;
(b)将较大的附聚物粉碎,得到控制释放种子;和
(c)继续进行机械加工,同时任选再加入低百分含量的载体或稀释剂。
(d)任选地重复步骤(c)和可能地重复步骤(b)一次或多次。
该方法能够以高产率(大于80%)得到所需大小范围的、具有所需反胺苯环醇或其盐的均匀释放速率的颗粒。
可将所得颗粒过筛,以除去任何过大或过小的物质,然后通过(例如)将其封入硬的明胶胶囊(其中含有所需剂量的活性物质)中或通过将其压成片制成所需的剂量单位。
在本发明的该方法中,优选在步骤(a)加入全部反胺苯环醇或其盐,以及所用的大部分疏水性易熔释放控制材料。在步骤(a)加入的易熔释放控制材料的量优选占在整个制备操作中加入的各成分的总量的10%-90%(w/w)、更优选20%-70%(w/w)。
该方法的步骤(a)可以在具有标准不锈钢衬里的常规高速混合器,例如Collette Vactron 75或相当的混合器中进行。对上述混合物进行加工,直到床温达到或超过约40℃,并且所得混合物具有粘结的粒状结构,在使用非聚集原料的情况下,其细度约为1-3mm至细粉。在下述实施方案中,该物质具有附聚物的外观,当其冷却至40℃以下时,具有结构完整性和耐手指压碎性。在此期间,该附聚物具有不规则的大小、形状和外观。
优选使该附聚物冷却。使其冷却的温度不是严格的,一般可采用的温度在室温至37℃范围内。
采用任何适宜的方法将该附聚物粉碎,使过大的附聚物细碎,并产生粉末与小颗粒(优选直径小于2mm)的混合物。目前优选使用Jackson Crockatt成粒机采用适宜大小的筛孔,或者采用具有合适尺寸筛的Comil进行分粒。我们发现,如果在前述装置中所用的筛孔尺寸太小,则在打浆机或高速搅拌机的作用下熔融的附聚物将使筛孔堵塞,并妨碍混合物进一步通过,因而降低收率。我们发现筛孔尺寸为12是合适的。
使分粒后的物质再返回高速混合器中并继续加工。据信这将使较细的颗粒粘固,形成大小范围均匀的颗粒。
在本发明方法的一种优选形式中,继续加工分粒后的物质,直到所用的疏水性易熔材料开始软化/熔融,并且然后任选添加附加的疏水性易熔材料。继续混合,直到该混合物已被转化成所需的预定大小范围的颗粒。
为了确保在高速混合器中对各成分的能量输入均匀,优选至少部分能量以微波能的方式提供。
也可以通过其他方式传送能量,例如通过加热套或借助混合器叶轮和切碎机叶片传送。
在颗粒形成后使其冷却或静置放冷,然后可将其过筛以除去任何过大或过小的物质。
所得颗粒可以按本身已知的方法用于制备本发明的剂量单位,例如片剂或胶囊剂。
我们还发现,按照PCT申请/SE93/00225中所述的熔融法和在我们的在先未公开英国申请9324045.5(于1993年11月23日提交)中所述和要求保护的方法以及本文所述方法制备的、含有反胺苯环醇或其盐的颗粒特别适用于加工成片剂。
我们发现,通过适当选择在形成颗粒和压片中所用的物质及其所用的比例,能够在很大程度上控制反胺苯环醇或其盐从所压制的片剂中的最终溶解和释放速率。
通常,为了形成本发明的片剂,将如上所述制备的颗粒与压片赋形剂如一种或多种标准赋形剂(例如稀释剂、润滑剂、粘合剂、流动助剂、崩解剂、表面活性剂或水溶性聚合材料)掺合。
适宜的稀释剂是例如微晶纤维素、乳糖和磷酸二钙。适宜的润滑剂是例如硬脂酸镁和富马酸硬脂基酯的钠盐。适宜的粘合剂是例如羟丙基甲基纤维素、聚乙烯吡咯烷酮和甲基纤维素。
适宜的崩解剂是淀粉、淀粉甘醇酸钠、交联聚乙烯吡咯烷酮(crospovidone)和croscarmalose sodium。
适宜的表面活性剂是Poloxamer 188、多乙氧基醚和十二烷基硫酸钠。
适宜的流动助剂是滑石、无水胶体二氧化硅。
适宜的水溶性聚合物是PEG,其分子量为1000-6000。
为了制备本发明的片剂,采用常规方法,例如采用Y-Cone或bin-blender,可将在本发明中制备的颗粒与所需赋形剂(如果有的话)混合或掺合,并且按照常规的压片方法、使用适宜尺寸的压片模将所得混合物压成片。可采用常规的压片机生产片剂,在下述实施方案中,可在标准的单冲头F3 Manesty机或Kilian RLE 15旋转压片机上制片。
一般来说,我们发现,尽管使用这种高水溶性活性剂。如反胺苯环醇或其盐,然而按标准方法压制形成的片剂中活性成分的释放速率仍然非常低,例如相应于大于24小时、例如大于36小时期间的释放。我们发现,可以以多种方式调节释放分布图。例如,较高的药物负荷可增加释放速率;在颗粒中使用较大比例的水溶性易熔材料、或者在片剂中使用较大比例的表面活性剂也会使活性成分有较高的释放速率。通过控制这些成分的相对含量,可以调节反胺苯环醇或其盐的释放分布图。
具体实施方式
为了使用人们更充分地了解本发明,仅以说明的方式给出下列实施例。
实施例1
制备具有下列配方的片剂:
mg/片
反胺苯环醇盐酸盐 100
乳糖Ph.Eur. 68.0
乙基纤维素(Surelease25%固体) 15
纯化水Ph.Eur. 13.3*
鲸蜡醇硬脂醇混合物Ph.Eur. 42.00
(Dehydag wax 0)
硬脂酸镁Ph.Eur. 2.00
纯化的滑石Ph.Eur. 3.00
230.00
*在加工过程中除去。
使反胺苯环醇盐(100mg)和乳糖(68mg)成粒,将其转移到流化床成粒机上,并用乙基纤维素(15mg)和水喷雾。然后将此颗粒在60℃干燥并通过1mm筛。
向含有反胺苯环醇的温热颗粒中加入熔融的鲸蜡醇硬脂醇混合物(42mg),并将所有物质彻底混合。使该颗粒放置冷却并筛过1.6mm筛。加入纯化的滑石和硬脂酸镁,并使其与该颗粒混合。然后将此颗粒压成片。
用具有下列配方的膜包衣对所述片进行包衣。
mg/片
羟丙基甲基纤维素 0.770
(Ph.Eur.15cps(Methocel E15))
羟丙基甲基纤维素 3.87
(Ph.Eur.5cps(Methocel E5))
Opaspray M~1-7111B(33%固体) 2.57
聚乙二醇400USNF 0.520
纯化的滑石Ph.Eur. 0.270
纯化水Ph.Eur. 55.52*
*在加工过程中除去。
实施例2
制备具有下列配方的片剂:
mg/片
反胺苯环醇盐酸盐 100.0
乳糖Ph.Eur. 58.0
乙基纤维素USNF 15.0
(Ethocel 45CP)
鲸蜡醇硬脂醇混合物Ph.Eur. 52.0
(Dehydag wax 0)
硬脂酸镁Ph.Eur. 2.00
纯化的滑石Ph.Eur. 3.00
将反胺苯环醇盐酸盐(100mg)、乳糖(58mg)和乙基纤维素(15mg)的混合物成粒,同时加入熔融的鲸蜡醇硬脂醇混合物(52mg),并将全部物质彻底混合。使该颗粒放置冷却,并筛过1.6mm筛。加入纯化的滑石和硬脂酸镁,并将其与所述颗粒混合。然后将该颗粒压成片,用具有实施例1中所给配方的膜包衣将所述片进行包衣。
实施例3
按照实施例2中所述方法制备具有下列配方的膜包衣片剂:
mg/片
反胺苯环醇盐酸盐 100.00
乳糖Ph.Eur. 70.50
羟乙基纤维素Ph.Eur. 12.50
鲸蜡醇硬脂醇混合物Ph.Eur. 42.00
硬脂酸镁Ph.Eur. 2.00
纯化的滑石Ph.Eur. 3.00
体外溶解研究
对上述制备的片剂进行体外溶解研究。结果列于表I中。
表I | |||
反胺苯环醇的释放WT% | |||
时间(小时) | 实施例1 | 实施例2 | 实施例3 |
1 | 39 | 35 | 43 |
2 | 52 | 47 | 60 |
4 | 67 | 62 | 84 |
8 | 82 | 78 | 97 |
12 | 90 | 86 |
*对片芯进行测量
在包括12名健康志愿者的实验中,发现在服用一片实施例2的片剂后,反胺苯环醇的血清含量如图1中所说明的那样。
实施例4和5
通过下列步骤制备具有下面表II所给配方的颗粒:
i.将成分(a)和(b)(一次投料总重量为0.7kg)装入带有变速混合及成粒叶片的10升容量的Collette Gral Mixer(或类似设备)的转筒中;
ii.在约150-1000rpm条件下混合各成分,同时加热至转筒中的内含物凝聚为止。
iii.使凝聚物质通过Comil和/或Jackson Crockatt使其分粒,得到控制释放种子。
iv.在10升Collette Gral的转筒中温热并混合经分粒的物质,直到形成所需预定尺寸的均匀多颗粒,其产率在于80%。此过程约需5分钟。
v.从混合器中倒出该多颗粒,并使其过筛,以分离出用0.5-2mm孔径筛收集的多颗粒。
表II | ||
实施例 | 4 | 5 |
(a)反胺苯环醇HCl(Wt%) | 50 | 75 |
(b)氢化植物油(Wt%) | 50 | 25 |
实施例6
采用Y-Cone或bin-blender将实施例4的颗粒样品与硬脂酸镁和纯化的滑石掺合。然后或者采用(1)14×6mm、(2)16×7mm或(3)18.6×7.5mm胶囊成型工具,在单冲头F3 Manesty压片机上将所掺合的混合物压片,得到含200、300和400mg反胺苯环醇HCl的片剂。每剂量单位中各成分的含量如下:
表III | |||
片成分 | MG/片 | ||
1 | 2 | 3 | |
反胺苯环醇盐酸盐 | 200 | 300 | 400 |
氢化植物油 | 200 | 300 | 400 |
小计 | 400 | 600 | 800 |
纯化的滑石 | 12.63 | 18.95 | 25.26 |
硬脂酸镁 | 8.42 | 12.63 | 16.84 |
通过采用Ph.Eur.Paddle Method 100rpm、0.1N HCl进行溶解,对各片进行评价。
用改进的Ph.Eur.Basket代替Ph.Eur.Paddle,以评价未压制的颗粒。
结果示于下列表IV中:
表IV | ||||
试验开始后的小时数 | 颗粒 | 片1 | 片2 | 片3 |
反胺苯环醇盐酸盐的释放% | ||||
1 | 54 | 16 | 15 | 15 |
2 | 68 | 23 | 20 | 21 |
3 | 76 | 28 | 25 | 25 |
4 | 82 | 32 | 28 | 28 |
6 | 89 | 40 | 35 | 35 |
8 | 93 | 46 | 41 | 40 |
10 | 96 | 50 | 45 | 45 |
12 | 98 | 55 | 49 | 49 |
16 | 100 | 63 | 57 | 56 |
20 | NR | 70 | 63 | NR |
这些结果证实了压片在降低释放速率方面的效力。
实施例7
采用与实施例3类似的方法,然后将实施例5的颗粒样品压片,每单位剂量中各成分的含量为:
表V | |||
片成分 | MG/片 | ||
4 | 5 | 6 | |
反胺苯环醇盐酸盐 | 200 | 300 | 400 |
氢化植物油 | 66.7 | 100 | 133 |
小计 | 266.7 | 400 | 533 |
纯化的滑石 | 7.63 | 11.44 | 15.25 |
硬脂酸镁 | 5.16 | 7.63 | 10.17 |
还是通过上述的溶解方法对各片剂及未压制的多颗粒样品(每一样品含400mg反胺苯环醇盐酸盐)进行评价。所得结果列于下面表VI中:
表VI | ||||
试验开始后的小时数 | 颗粒 | 片4 | 片5 | 片6 |
反胺苯环醇盐酸盐的释放% | ||||
1 | 77 | 43 | 40 | 42 |
2 | 92 | 64 | 55 | 56 |
3 | 98 | 75 | 65 | 66 |
4 | 100 | 83 | 72 | 73 |
6 | 102 | 94 | 83 | 84 |
8 | 102 | 100 | 91 | 91 |
10 | 102 | NR | 96 | 97 |
这些结果表明,通过增加高水溶性反胺苯环醇盐酸盐的负荷(在此实施例中为75%w/w,与在实施例6中50%w/w的负荷相比较)可以实现活性成分的释放速率的显著加快。
实施例8
重复实施例4,所不同的是采用下列配方:
反胺苯环醇HCl 200mg/片
氢化植物油 163.0mg/片
如实施例6所述,将所得多颗粒与下列成分掺合:
纯化的滑石 11.5mg/片
硬脂酸镁 7.66mg/片
如实施例6所述,将掺合物压片,所不同的是使用15mm×6.5mm正常凹的胶囊成型平面/平面冲头。
通过上述溶解方法评价所得的片剂。所得结果示于表VIII中:
表VII
试验开始后的小时数 | 反胺苯环醇盐酸盐的释放% |
1 | 20 |
2 | 27 |
3 | 32 |
4 | 37 |
6 | 44 |
8 | 50 |
10 | 55 |
12 | 60 |
16 | 67 |
20 | 73 |
24 | 77 |
在包括5名健康男性志愿者的实验中,由单剂量给药上述片剂与给药市售的反胺苯环醇滴剂100mg比较,所得血浆分布图如图2所示。
Claims (4)
1.一种单剂形式的药物制剂,包括含颗粒尺寸为0.1至3.0毫米的多枚颗粒的片剂或胶囊剂,且含有作为活性成分的反胺苯环醇或其药物可接受盐,该活性成分包含在药物可按受赋形剂基质中,其特征在于该活性成分是反胺苯环醇或其药物可接受盐,该单剂含有50-400毫克反胺苯环醇,反胺苯环醇按照反胺苯环醇盐酸盐计算,且该基质主要由疏水可熔融物质组成,选自氢化植物油、氢化蓖麻油、微晶蜡、蜂蜡、巴西棕榈蜡和甘油单硬脂酸酯,活性物质总量占制剂重量的10%-90%。
2.权利要求1的药物制剂,该片剂或多颗粒制剂由氢化植物油和活性成分组成。
3.权利要求1或2的药物制剂,呈由压缩多枚颗粒制得的片剂形式。
4.制备权利要求1的药物制剂的方法,包括在本身已知的高速混合机内放置颗粒形式的反胺苯环醇或其药物可接受盐和颗粒状疏水可溶融物质;所述疏水可溶融物质选自氢化植物油、氢化蓖麻油、微晶蜡、蜂蜡、巴西棕榈蜡和甘油单硬脂酸酯;活性物质总量占制剂重量的10%-90%,且在每一最终制剂单元中提供50-400毫克活性成分;所得混合物在高速混合物机内在一定速度下进行机械处理,并通过加热套和/或微波辐射注入能量至床体温度达到40℃或更高,混合物溶融或软化并形成聚结体,聚结体具有连续的颗粒质地,其尺寸、形状和外观不统一;打碎聚结体形成粉末和细小颗粒的混合物;然后在该高速混合器内继续进行机械加工,直至得到的颗粒尺寸范围是0.1-3.0毫米,颗粒或者被装入胶囊,或者压缩成片剂,使得到的每一胶囊或片剂含50-400毫克的活性成分。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4315525.1 | 1993-05-10 | ||
DE4315525A DE4315525B4 (de) | 1993-05-10 | 1993-05-10 | Pharmazeutische Zusammensetzung |
GB9324045.5 | 1993-11-23 | ||
GB9324045A GB2284760B (en) | 1993-11-23 | 1993-11-23 | A method of preparing pharmaceutical compositions by melt pelletisation |
GB9404544A GB9404544D0 (en) | 1994-03-09 | 1994-03-09 | Controlled release formulation |
GB9404544.0 | 1994-03-09 | ||
GB9404928.5 | 1994-03-14 | ||
GB9404928A GB2287880A (en) | 1994-03-14 | 1994-03-14 | Production of sustained release compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94105356A Division CN1094755C (zh) | 1993-05-10 | 1994-05-10 | 含反胺苯环醇或其盐的控制释放制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1240132A CN1240132A (zh) | 2000-01-05 |
CN1146410C true CN1146410C (zh) | 2004-04-21 |
Family
ID=27435744
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94105356A Expired - Lifetime CN1094755C (zh) | 1993-05-10 | 1994-05-10 | 含反胺苯环醇或其盐的控制释放制剂 |
CNB991066421A Expired - Lifetime CN1146410C (zh) | 1993-05-10 | 1999-05-17 | 控制释放制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94105356A Expired - Lifetime CN1094755C (zh) | 1993-05-10 | 1994-05-10 | 含反胺苯环醇或其盐的控制释放制剂 |
Country Status (22)
Country | Link |
---|---|
US (6) | US5591452A (zh) |
EP (6) | EP1468679B1 (zh) |
JP (3) | JP3045924B2 (zh) |
CN (2) | CN1094755C (zh) |
AT (5) | ATE468850T1 (zh) |
AU (2) | AU6196394A (zh) |
CA (1) | CA2123160C (zh) |
CZ (1) | CZ288517B6 (zh) |
DE (8) | DE09004973T8 (zh) |
DK (4) | DK1468679T3 (zh) |
ES (5) | ES2346651T3 (zh) |
FI (3) | FI942092A (zh) |
GR (2) | GR3020084T3 (zh) |
HU (1) | HU228177B1 (zh) |
ID (1) | ID25988A (zh) |
IL (3) | IL119660A (zh) |
NO (3) | NO306446B1 (zh) |
NZ (1) | NZ260408A (zh) |
PT (3) | PT1468679E (zh) |
SG (1) | SG67347A1 (zh) |
SK (2) | SK279971B6 (zh) |
TW (1) | TW496736B (zh) |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
DE4329794C2 (de) * | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5698210A (en) | 1995-03-17 | 1997-12-16 | Lee County Mosquito Control District | Controlled delivery compositions and processes for treating organisms in a column of water or on land |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
GB9519363D0 (en) * | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
DE69826113T2 (de) * | 1997-03-11 | 2005-01-20 | Arakis Ltd., Saffron Walden | R- und s- enantiomere getrennteteile enthaltende dosierungsformen |
DE19710008A1 (de) * | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
AU8293498A (en) | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
DE19729487A1 (de) * | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
UA53774C2 (uk) * | 1997-12-22 | 2003-02-17 | Еро-Селтік, С.А. | Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди |
WO1999032119A1 (en) * | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
JP4367722B2 (ja) * | 1998-04-17 | 2009-11-18 | 大正製薬株式会社 | マルチプルユニットタイプ徐放性錠剤 |
WO1999053905A1 (fr) * | 1998-04-17 | 1999-10-28 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee a unites multiples |
US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
US20060128806A1 (en) * | 1998-05-28 | 2006-06-15 | Medical Research Institute | Controlled release arginine alpha-ketoglutarate |
US6264974B1 (en) | 1998-07-07 | 2001-07-24 | Salvagnini Italia Spa | Buccal and sublingual administration of physostigmine |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
DE29818454U1 (de) * | 1998-10-15 | 1999-01-14 | Euro Celtique Sa | Opioid-Analgetikum |
WO2000040205A2 (en) * | 1999-01-05 | 2000-07-13 | Copley Pharmaceutical Inc. | Sustained release formulation with reduced moisture sensitivity |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
ES2226886T3 (es) * | 1999-08-31 | 2005-04-01 | Grunenthal Gmbh | Forma de administracion de accion retardada que contiene sacarinato de tramadol. |
SK285128B6 (sk) * | 1999-12-28 | 2006-07-07 | Zentiva, A. S. | Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy |
HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
DE60107393T2 (de) | 2000-03-01 | 2005-12-01 | Euro-Celtique S.A. | Verwendung von tramadol zur herstellung eines arzneimittels zur behandlung von funktionelle gastrointestinale krankenheiten |
IL155102A0 (en) * | 2000-10-03 | 2003-10-31 | Penwest Pharmaceuticals Co | Delivery system for multi-pharmaceutical active materials at various release rates |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
DE60211689T2 (de) | 2001-03-16 | 2007-01-11 | DMI Biosciences, Inc., Englewood | Verwendung von Tramadol zur Verzögerung der Ejakulation |
US7858118B2 (en) * | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
ATE493130T1 (de) | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
US7052706B2 (en) * | 2001-06-08 | 2006-05-30 | Nostrum Pharmaceuticals, Inc. | Control release formulation containing a hydrophobic material as the sustained release agent |
US7968119B2 (en) * | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
DE60230632D1 (de) * | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | Pharmazeutische kombinationen von oxycodon und naloxon |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
WO2003013433A2 (en) * | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
ATE431738T1 (de) | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
US6479060B1 (en) * | 2001-09-04 | 2002-11-12 | Healthpoint, Ltd. | Elegant hydrogenated castor oil ointments |
MXPA04002980A (es) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas. |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
SI1443917T1 (sl) * | 2001-11-07 | 2006-06-30 | Synthon Bv | Tablete tamsulozina |
KR20030060730A (ko) * | 2002-01-09 | 2003-07-16 | 하나제약 주식회사 | 난용성 약물의 서방화 제제 조성물 |
SI1476138T1 (sl) * | 2002-02-21 | 2012-07-31 | Valeant Internat Barbados Srl | Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
CN1642532A (zh) * | 2002-03-22 | 2005-07-20 | 西拉格股份公司 | 曲马多缓释制剂 |
EP2243471A1 (en) * | 2002-04-05 | 2010-10-27 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US7125563B2 (en) * | 2002-04-12 | 2006-10-24 | Dava Pharmaceuticals, Inc. | Sustained release pharmaceutical preparations and methods for producing the same |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
KR20050047507A (ko) * | 2002-06-27 | 2005-05-20 | 시락 아게 | 구형 펠렛 제제 |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
EP1545468A4 (en) * | 2002-09-20 | 2007-06-20 | Alpharma Inc | SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE |
JP5189242B2 (ja) * | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | 乱用抵抗性の医薬組成物 |
UA84277C2 (ru) * | 2002-10-25 | 2008-10-10 | Лабофарм Инк. | Композиция трамадола с пролонгированным высвобождением с 24-часовым действием |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
EP1558935B1 (en) * | 2002-10-25 | 2008-07-09 | Labopharm Inc. | Controlled-release compositions |
CN1942175B (zh) * | 2002-10-25 | 2010-05-26 | 莱博法姆公司 | 24小时有效的曲马多缓释制剂 |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
JP2006514986A (ja) * | 2002-12-13 | 2006-05-18 | シラグ・アクチエンゲゼルシヤフト | トラマドールおよびトピラメートを含んでなる制御放出調製物 |
DE10300325A1 (de) | 2003-01-09 | 2004-07-22 | Hexal Ag | Granulat mit öliger Substanz, Herstellungsverfahren und Tablette |
CN100500130C (zh) * | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | 缓释制剂及其制备方法 |
US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
EP1905435A3 (en) | 2003-03-11 | 2008-05-14 | Euro-Celtique S.A. | Titration dosing regimen for controlled release tramadol |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US8778382B2 (en) | 2003-04-30 | 2014-07-15 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20090304793A1 (en) * | 2003-09-22 | 2009-12-10 | Alpharma, Inc. | Sustained release opioid formulations and methods of use |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
WO2006079550A2 (en) * | 2005-01-28 | 2006-08-03 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
WO2006004719A2 (en) | 2004-06-25 | 2006-01-12 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
JP2008507508A (ja) * | 2004-07-22 | 2008-03-13 | 株式會社アモーレパシフィック | トピラメート徐放性製剤及びその製造方法 |
CA2596548A1 (en) * | 2005-01-31 | 2006-08-03 | Kyorin Pharmaceutical Co., Ltd. | Multiple unit oral sustained release preparation and process for production of the same |
BG66008B1 (bg) * | 2005-02-01 | 2010-10-29 | Cooperative Clinical Drug Research And Development Ag | Лекарствен препарат с изменено освобождаване |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
JP5095615B2 (ja) | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | ブプロピオン塩の放出調整製剤 |
EP1917000A2 (en) * | 2005-07-07 | 2008-05-07 | Farnam Companies, Inc. | Sustained release pharmaceutical compositions for highly water soluble drugs |
KR101655455B1 (ko) | 2005-09-09 | 2016-09-07 | 안젤리니 라보팜 엘엘씨 | 일일 1회 투여를 위한 트라조돈 조성물 |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US8329744B2 (en) * | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
WO2008134071A1 (en) * | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
CN101400343B (zh) | 2006-03-16 | 2012-01-11 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
PL2002828T3 (pl) * | 2006-03-30 | 2019-11-29 | Nippon Zoki Pharmaceutical Co | Stały preparat farmaceutyczny |
US20070264335A1 (en) * | 2006-05-09 | 2007-11-15 | Sherman Bernard C | Modified release tablets comprising tramadol |
CN101677963B (zh) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | 药物组合物 |
US20080075771A1 (en) * | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
BRPI0807281A2 (pt) * | 2007-02-12 | 2014-04-29 | Dmi Biosciences Inc | Reduzindo os efeitos colaterais de tramadol |
BRPI0807282A2 (pt) * | 2007-02-12 | 2014-04-29 | Dmi Biosciences Inc | Tratamento de ejaculação precoce e disfunção erétil co-mórbidas |
ATE476176T1 (de) * | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
US20080026054A1 (en) * | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
WO2009018169A1 (en) * | 2007-07-27 | 2009-02-05 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
CZ300468B6 (cs) * | 2007-09-20 | 2009-05-27 | Zentiva, A. S | Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy |
US20090081291A1 (en) * | 2007-09-26 | 2009-03-26 | Gin Jerry B | Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User |
AU2008314454A1 (en) * | 2007-10-16 | 2009-04-23 | Labopharm (Barbados) Limited | Bilayer composition for the sustained release of acetaminophen and tramadol |
JP5651818B2 (ja) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | 誤用を防止するための放出制御製剤 |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
US20090246276A1 (en) * | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
ES2599031T3 (es) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización |
GB0811024D0 (en) * | 2008-06-17 | 2008-07-23 | E Therapeutics Plc | Sustained release treatment of depression |
US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
BRPI0910780A2 (pt) * | 2008-07-07 | 2016-08-09 | Euro Celtique Sa | uso de antagonistas de opióides para o tratamento da retenção urinária |
WO2010014952A2 (en) | 2008-07-31 | 2010-02-04 | Clarke Mosquito Control Products, Inc. | Extended release tablet and method for making and using same |
CA2746888C (en) | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
WO2010099508A1 (en) | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
EP2403487A2 (en) * | 2009-03-04 | 2012-01-11 | Fdc Limited | Oral controlled release dosage forms for water soluble drugs |
DK2405915T3 (en) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
US8811578B2 (en) * | 2009-03-23 | 2014-08-19 | Telemanager Technologies, Inc. | System and method for providing local interactive voice response services |
DE102009019268A1 (de) * | 2009-04-28 | 2010-11-11 | Lts Lohmann Therapie-Systeme Ag | Arzneimittel mit poröser Matrix |
NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
PT2456424E (pt) * | 2009-07-22 | 2013-09-30 | Gruenenthal Gmbh | Forma de dosagem resistente à adulteração e estabilizada contra a oxidação |
KR20120059582A (ko) * | 2009-08-31 | 2012-06-08 | 데포메드 인코퍼레이티드 | 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물 |
US20110104272A1 (en) * | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
WO2011095314A2 (en) * | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
EP2371356B1 (en) * | 2010-03-12 | 2012-12-19 | Phoeme GmbH | Multi-particle pharmaceutical formulation for colon absorption |
US20120009261A1 (en) | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro-retentive dosage forms |
CA2808541C (en) | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
WO2012129551A1 (en) | 2011-03-23 | 2012-09-27 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
RS57913B1 (sr) | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
DE102013009114A1 (de) | 2013-05-29 | 2014-12-04 | Franz Gerstheimer | Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
WO2014205228A1 (en) * | 2013-06-19 | 2014-12-24 | Orbis Biosciences, Inc. | Tramadol particle formulations and methods |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
KR20180037074A (ko) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
CN106109431B (zh) * | 2015-12-18 | 2020-11-10 | 上海奕利制药有限公司 | 一种缓控释微丸片剂及其制备方法 |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
WO2019087084A1 (en) | 2017-11-02 | 2019-05-09 | Eman Biodiscoveries Sd. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
WO2020086673A1 (en) * | 2018-10-26 | 2020-04-30 | Guangzhou Dazhou Biomedicine Ltd. | Ketamine oral transmucosal delivery system |
US11000488B2 (en) | 2019-03-22 | 2021-05-11 | Syntrix Biosystems Inc. | Treating pain using desmetramadol |
US11103452B2 (en) * | 2019-11-08 | 2021-08-31 | Athena Bioscience, Llc | Tramadol hydrochloride solution |
US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
JP7435915B2 (ja) | 2021-07-19 | 2024-02-21 | 三菱自動車工業株式会社 | 排気還流システムの故障診断装置 |
Family Cites Families (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US266331A (en) * | 1882-10-24 | walmsley | ||
US2738303A (en) | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
DE1199764B (de) | 1963-04-02 | 1965-09-02 | Gruenenthal Chemie | Verfahren zur Herstellung von basisch substituierten Phenolaethern |
US4132753A (en) * | 1965-02-12 | 1979-01-02 | American Cyanamid Company | Process for preparing oral sustained release granules |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US3830934A (en) * | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
GB1405088A (en) | 1971-06-03 | 1975-09-03 | Mundipharma Ag | Slow release formulation |
FR2183546B1 (zh) | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
DE2360796B2 (de) * | 1973-12-06 | 1977-06-02 | Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
US3974157A (en) * | 1974-03-04 | 1976-08-10 | Pennwalt Corporation | 1-(Amino-alkyl)-2-aryl-cyclohexane alcohols and esters |
DE2426812A1 (de) * | 1974-06-04 | 1976-01-02 | Klinge Co Chem Pharm Fab | Verfahren zur herstellung von granulaten |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4076798A (en) * | 1975-05-29 | 1978-02-28 | American Cyanamid Company | High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4366172A (en) * | 1977-09-29 | 1982-12-28 | The Upjohn Company | 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
JPS56140915A (en) * | 1980-04-07 | 1981-11-04 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for solid drug |
DE3024416C2 (de) | 1980-06-28 | 1982-04-15 | Gödecke AG, 1000 Berlin | Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung |
JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
DE3124983A1 (de) | 1981-06-25 | 1983-01-20 | Meditest Inst Fuer Medizinisch | Arzneiformen zur oralen verabreichung |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4421436A (en) * | 1982-07-06 | 1983-12-20 | Texaco Development Corporation | Tension leg platform system |
ZA836627B (en) | 1982-10-08 | 1984-05-30 | Verex Lab | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
EP0152379A3 (de) | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
GB8405112D0 (en) * | 1984-02-28 | 1984-04-04 | Akzo Nv | Anti-arrhythmic amino-alcohols |
US4894234A (en) | 1984-10-05 | 1990-01-16 | Sharma Shri C | Novel drug delivery system for antiarrhythmics |
EP0189861A3 (en) | 1985-01-26 | 1988-02-17 | Showa Denko Kabushiki Kaisha | Percutaneous absorption accelerator for ionic water-soluble medicine |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
NL8500724A (nl) * | 1985-03-13 | 1986-10-01 | Univ Groningen | Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. |
EP0204951B1 (en) | 1985-05-13 | 1993-01-20 | Miles Inc. | Use of calcium channel blockers in the production of compositions for withdrawal symptoms |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
JPS61293911A (ja) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4940665A (en) | 1985-12-27 | 1990-07-10 | Showa Denko K. K. | Method for granulation of enzyme |
DE3602370A1 (de) | 1986-01-27 | 1987-08-06 | Chrubasik Sigrun | Verwendung von analgetica durch inhalation |
GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
DE3623193A1 (de) | 1986-07-10 | 1988-01-14 | Gruenenthal Gmbh | Neue verbindungen, diese enthaltende arzneimittel und verfahren zu deren herstellung |
JPH0816066B2 (ja) | 1986-07-18 | 1996-02-21 | エーザイ株式会社 | 持続性薬効製剤 |
US4970075A (en) * | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4760094A (en) | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
ZA882783B (en) | 1987-06-10 | 1988-10-20 | Warner-Lambert Company | Process for preparing a pharmaceutical composition |
DE3721721C1 (de) * | 1987-07-01 | 1988-06-09 | Hoechst Ag | Verfahren zur Umhuellung von Granulaten |
GB8717168D0 (en) | 1987-07-21 | 1987-08-26 | Roussel Lab Ltd | Controlled-release device |
JPH01149717A (ja) * | 1987-12-04 | 1989-06-12 | Showa Denko Kk | 直腸内投与用医薬組成物 |
EP0327295A3 (en) | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
US5472710A (en) | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
DE3812799A1 (de) | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung |
JP2681373B2 (ja) | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | 徐放性製剤の製造法 |
US4925675A (en) * | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
DE68916497T2 (de) | 1988-09-30 | 1994-11-17 | Rhone Poulenc Rorer Ltd | Pharmazeutisches Granulat. |
US5178868A (en) | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
NZ231281A (en) | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5196203A (en) | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
US5330766A (en) * | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
CA2007055A1 (en) | 1989-01-06 | 1990-07-06 | Garth Boehm | Theophylline dosage form |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
FR2642420B1 (fr) | 1989-01-27 | 1991-09-06 | Valpan Sa Labo Pharma | Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
JPH0642655Y2 (ja) * | 1989-05-12 | 1994-11-09 | トミー株式会社 | フック付歯科矯正用ブラケット |
DK161743C (da) | 1989-07-03 | 1992-02-17 | Niro Atomizer As | Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale |
JPH03163030A (ja) | 1989-08-28 | 1991-07-15 | Arizona Technol Dev Corp | アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法 |
US5169645A (en) * | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
IL96311A (en) | 1989-12-01 | 1995-05-26 | Abbott Lab | Medications with delayed release |
JPH04217925A (ja) * | 1990-03-27 | 1992-08-07 | Nippon Saafuakutanto Kogyo Kk | 新規な解熱消炎鎮痛剤組成物 |
DE69123075T2 (de) | 1990-04-12 | 1997-03-20 | Shionogi Seiyaku Kk | Ueberzogene Zusammensetzung sowie Verfahren zu ihrer Herstellung |
HU208495B (en) | 1990-06-27 | 1993-11-29 | Alkaloida Vegyeszeti Gyar | Process for producing retarde pharmaceutical compositions |
WO1992001446A1 (en) * | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
FR2665357B1 (fr) * | 1990-07-31 | 1995-03-31 | Aiache Jean Marc | Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee. |
GB2246514B (en) | 1990-08-01 | 1993-12-15 | Scras | Sustained release pharmaceutical compositions and the preparation of particles for use therein |
DE59105613D1 (de) | 1990-08-24 | 1995-07-06 | Spirig Ag | Verfahren zur Herstellung von Pellets. |
JP2875611B2 (ja) * | 1990-08-29 | 1999-03-31 | エーザイ株式会社 | ケイ酸カルシウム含有外用剤 |
DE4031881C2 (de) | 1990-10-08 | 1994-02-24 | Sanol Arznei Schwarz Gmbh | Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung |
SE9003296L (sv) * | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | Foerfarande foer att formulera laekemedel |
US5271934A (en) * | 1990-10-22 | 1993-12-21 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
US5603956A (en) | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5132142A (en) | 1991-03-19 | 1992-07-21 | Glatt Gmbh | Apparatus and method for producing pellets by layering power onto particles |
IT1245891B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
MX9205106A (es) | 1991-09-06 | 1993-05-01 | Johnson & Johnson | Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
GB9121204D0 (en) | 1991-10-04 | 1991-11-20 | Euro Celtique Sa | Medicament |
WO1993007859A1 (en) * | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
AU661723B2 (en) | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
GB2287880A (en) | 1994-03-14 | 1995-10-04 | Euro Celtique Sa | Production of sustained release compositions |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5167964A (en) | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
SE9200858L (sv) * | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
JP2568202Y2 (ja) | 1992-10-13 | 1998-04-08 | オリエンタル写真工業株式会社 | ロール状材料用マガジン |
DE4236752A1 (de) | 1992-10-30 | 1994-05-05 | Asta Medica Ag | Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5616343A (en) | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
SE9301057L (sv) * | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
IL109944A (en) | 1993-07-01 | 1998-12-06 | Euro Celtique Sa | Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
CA2173818A1 (fr) | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
AU8293498A (en) | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
UA53774C2 (uk) | 1997-12-22 | 2003-02-17 | Еро-Селтік, С.А. | Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди |
US6284273B1 (en) | 1998-02-24 | 2001-09-04 | Vincent Lenaerts | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
US6607748B1 (en) | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
US6338859B1 (en) | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
-
1994
- 1994-04-27 IL IL11966094A patent/IL119660A/en not_active IP Right Cessation
- 1994-04-27 NZ NZ260408A patent/NZ260408A/en not_active IP Right Cessation
- 1994-04-27 IL IL109460A patent/IL109460A/en not_active IP Right Cessation
- 1994-04-29 ES ES04030658T patent/ES2346651T3/es not_active Expired - Lifetime
- 1994-04-29 DK DK04014719T patent/DK1468679T3/da active
- 1994-04-29 DK DK04030658.1T patent/DK1527775T3/da active
- 1994-04-29 DK DK94303128.6T patent/DK0624366T3/da active
- 1994-04-29 AT AT04030658T patent/ATE468850T1/de active
- 1994-04-29 EP EP04014719A patent/EP1468679B1/en not_active Expired - Lifetime
- 1994-04-29 DE DE09004973T patent/DE09004973T8/de active Active
- 1994-04-29 EP EP95114527A patent/EP0699436B2/en not_active Expired - Lifetime
- 1994-04-29 EP EP96101147A patent/EP0729751A1/en not_active Ceased
- 1994-04-29 ES ES04014719T patent/ES2247574T3/es not_active Expired - Lifetime
- 1994-04-29 DE DE69400215T patent/DE69400215T2/de not_active Revoked
- 1994-04-29 ES ES09004973T patent/ES2331046T1/es active Pending
- 1994-04-29 EP EP04030658A patent/EP1527775B1/en not_active Expired - Lifetime
- 1994-04-29 DE DE0729751T patent/DE729751T1/de active Pending
- 1994-04-29 DE DE69427472T patent/DE69427472T3/de not_active Expired - Lifetime
- 1994-04-29 PT PT04014719T patent/PT1468679E/pt unknown
- 1994-04-29 PT PT04030658T patent/PT1527775E/pt unknown
- 1994-04-29 DK DK95114527.5T patent/DK0699436T4/da active
- 1994-04-29 AT AT04014719T patent/ATE303140T1/de active
- 1994-04-29 AT AT95114527T patent/ATE201989T1/de active
- 1994-04-29 DE DE9422335U patent/DE9422335U1/de not_active Expired - Lifetime
- 1994-04-29 EP EP94303128A patent/EP0624366B1/en not_active Revoked
- 1994-04-29 AT AT94303128T patent/ATE138566T1/de not_active IP Right Cessation
- 1994-04-29 DE DE69434479T patent/DE69434479T2/de not_active Expired - Lifetime
- 1994-04-29 ES ES94303128T patent/ES2088312T3/es not_active Expired - Lifetime
- 1994-04-29 SG SG1996008705A patent/SG67347A1/en unknown
- 1994-04-29 PT PT95114527T patent/PT699436E/pt unknown
- 1994-04-29 EP EP09004973.5A patent/EP2103303B1/en not_active Expired - Lifetime
- 1994-04-29 DE DE0699436T patent/DE699436T1/de active Pending
- 1994-04-29 DE DE69435295T patent/DE69435295D1/de not_active Expired - Lifetime
- 1994-04-29 ES ES95114527T patent/ES2159591T5/es not_active Expired - Lifetime
- 1994-05-04 CZ CZ19941093A patent/CZ288517B6/cs not_active IP Right Cessation
- 1994-05-06 HU HU9401478A patent/HU228177B1/hu unknown
- 1994-05-06 FI FI942092A patent/FI942092A/fi not_active Application Discontinuation
- 1994-05-09 AU AU61963/94A patent/AU6196394A/en not_active Abandoned
- 1994-05-09 NO NO941719A patent/NO306446B1/no not_active IP Right Cessation
- 1994-05-09 CA CA002123160A patent/CA2123160C/en not_active Expired - Lifetime
- 1994-05-10 SK SK541-94A patent/SK279971B6/sk not_active IP Right Cessation
- 1994-05-10 JP JP6096671A patent/JP3045924B2/ja not_active Expired - Lifetime
- 1994-05-10 US US08/241,129 patent/US5591452A/en not_active Expired - Lifetime
- 1994-05-10 ID IDP991104D patent/ID25988A/id unknown
- 1994-05-10 SK SK1437-98A patent/SK283143B6/sk not_active IP Right Cessation
- 1994-05-10 CN CN94105356A patent/CN1094755C/zh not_active Expired - Lifetime
- 1994-05-12 TW TW085103273A patent/TW496736B/zh not_active IP Right Cessation
-
1995
- 1995-05-24 US US08/449,772 patent/US6326027B1/en not_active Expired - Lifetime
-
1996
- 1996-05-30 GR GR960401422T patent/GR3020084T3/el unknown
- 1996-07-10 US US08/677,798 patent/US6254887B1/en not_active Expired - Lifetime
- 1996-11-20 IL IL11966096A patent/IL119660A0/xx unknown
-
1997
- 1997-10-07 AU AU39957/97A patent/AU3995797A/en not_active Abandoned
-
1998
- 1998-08-14 JP JP22971898A patent/JP3267561B2/ja not_active Expired - Lifetime
-
1999
- 1999-05-17 CN CNB991066421A patent/CN1146410C/zh not_active Expired - Lifetime
- 1999-07-15 NO NO19993484A patent/NO313124B1/no not_active IP Right Cessation
- 1999-11-25 AT AT0081699U patent/AT3413U3/de not_active IP Right Cessation
-
2001
- 2001-03-06 US US09/800,204 patent/US7074430B2/en not_active Expired - Fee Related
- 2001-07-19 NO NO20013566A patent/NO331650B1/no unknown
- 2001-09-06 GR GR20010401419T patent/GR3036565T3/el unknown
- 2001-09-27 JP JP2001297270A patent/JP3443574B2/ja not_active Expired - Lifetime
-
2003
- 2003-04-14 FI FI20030560A patent/FI121565B/fi not_active IP Right Cessation
-
2006
- 2006-05-16 US US11/435,015 patent/US20060269603A1/en not_active Abandoned
-
2008
- 2008-05-14 US US12/152,474 patent/US20090117191A1/en not_active Abandoned
-
2010
- 2010-08-17 FI FI20105856A patent/FI122717B/fi not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1146410C (zh) | 控制释放制剂 | |
CN1198596C (zh) | 24小时释放甲氧乙心安的持续释放制剂 | |
CN1168094A (zh) | 可直接压制的高负荷扑热息痛制剂 | |
CN88101104A (zh) | 药物片剂、药物粒剂及其制备方法 | |
CN1080169A (zh) | 含有水溶性药物的控释片 | |
CN1874767A (zh) | 包含aplindore和其衍生物的缓释药物组合物 | |
CN1747723A (zh) | 含活性成分混合物的组合物及其制备方法 | |
CN1762357A (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
CN1235544A (zh) | 盐酸[R-(Z)]-α-甲氧亚氨基-α-(1-氮杂双环[2.2.2]辛-3-基)乙腈控释剂型 | |
CN1813728A (zh) | 包有肠溶薄膜衣的奥美拉唑锌口服固体制剂、口服半固体制剂及其制备方法 | |
CN1203845C (zh) | 含有普鲁芬的药物组合物 | |
CN1102323A (zh) | 缓释组合物及制备药用组合物的方法 | |
AU2009243527B8 (en) | Controlled release formulation | |
AU2004229058B9 (en) | Controlled release formulation | |
CN1568180A (zh) | 控制释放4-氨基-6,7-二甲氧基-2-(5-甲磺酰氨基-1,2,3,4-四氢异喹啉-2-基)-5-(2-吡啶基)喹唑啉的药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20140510 Granted publication date: 20040421 |